Sinovac Biotech Ltd. (Nasdaq:SVA - News), a leading provider of biopharmaceutical products in China, announced it submitted the application to commence clinical trials for its 13-valent pneumococcal conjugate vaccine (PCV) to China's State Food and Drug Administration (SFDA) on March 3, 2011. Sinovac initiated its PCV research program in 2008. The vaccine targets infants under two years old. The target population in Chinais estimated at 34 million...
Read from Source
|
